Peer-reviewed veterinary case report
Serum thymidine kinase activity in clinically healthy and diseased horses: a potential marker for lymphoma.
- Journal:
- Veterinary journal (London, England : 1997)
- Year:
- 2015
- Authors:
- Larsdotter, S et al.
- Affiliation:
- University Animal Hospital
- Species:
- horse
Abstract
Serum thymidine kinase (sTK) activity is a tumour marker used as a prognostic indicator for lymphoma in humans, dogs and cats. The aim of this study was to evaluate the clinical utility of sTK as a biomarker for lymphoma in horses. Serum samples were collected from clinically normal horses (n = 37), horses with lymphoma (n = 23), horses with non-haematopoietic neoplasia (n = 9) and horses with inflammatory disease (n = 14). sTK was measured using a radioenzyme assay. A reference cut-off value of <2.7 U/L (mean + 2 standard deviations, SDs) was established using data from clinically normal horses. sTK activity (mean ± SD) was 26.3 ± 91.5 U/L (range 0.8-443 U/L) for horses with lymphoma, 2.3 ± 1.4 U/L (range 0.6-5.7 U/L) for horses with non-haematopoietic neoplasia and 1.5 ± 0.6 U/L (range 0.6-2.8 U/L) for horses with inflammatory disease. Horses with lymphoma had significantly higher sTK activity than horses without clinical signs of disease (P <0.01), horses with inflammatory disease (P <0.01) and horses with non-haematopoietic neoplasia (P <0.05). sTK activity is a potentially useful biomarker for equine lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/25744802/